Anti-CTLA-4 drugs inhibit CTLA-4 + Treg cells in tumors and intestines, leading to the activation of effector T cells like cytotoxic T-lymphocytes (CTLs) and resulting in ICI colitis [16]. Here, CTLA4 is linked to colitis.